BioNTech (NASDAQ:BNTX) Price Target Cut to $122.00

BioNTech (NASDAQ:BNTX) had its price target dropped by equities researchers at BMO Capital Markets from $123.00 to $122.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. BMO Capital Markets’ target price would indicate a potential upside of 35.36% from the company’s current price.

Other research analysts also recently issued research reports about the stock. HC Wainwright restated a “buy” rating and issued a $107.00 price target on shares of BioNTech in a research report on Wednesday, April 17th. UBS Group cut their price target on shares of BioNTech from $110.00 to $101.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 27th. JPMorgan Chase & Co. lowered their price objective on BioNTech from $99.00 to $90.00 and set an “underweight” rating for the company in a research report on Friday, March 22nd. Canaccord Genuity Group restated a “buy” rating and set a $171.00 target price on shares of BioNTech in a research report on Thursday, March 21st. Finally, The Goldman Sachs Group lowered their target price on BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a report on Wednesday, February 28th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, BioNTech has an average rating of “Hold” and a consensus target price of $118.82.

BioNTech Stock Down 0.8 %

Shares of NASDAQ:BNTX opened at $90.13 on Tuesday. The firm has a market cap of $21.43 billion, a P/E ratio of 21.88 and a beta of 0.25. BioNTech has a 12-month low of $85.21 and a 12-month high of $125.83. The business has a fifty day simple moving average of $90.47 and a 200 day simple moving average of $95.95. The company has a quick ratio of 9.26, a current ratio of 9.43 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Wednesday, March 20th. The company reported $2.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.64 by ($0.59). The company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $2.04 billion. BioNTech had a return on equity of 4.60% and a net margin of 24.26%. Analysts predict that BioNTech will post -1.74 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in BNTX. Cambridge Investment Research Advisors Inc. lifted its position in shares of BioNTech by 3.9% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 3,980 shares of the company’s stock worth $432,000 after buying an additional 148 shares in the last quarter. Raymond James & Associates increased its position in shares of BioNTech by 5.6% during the 3rd quarter. Raymond James & Associates now owns 5,579 shares of the company’s stock valued at $606,000 after purchasing an additional 298 shares during the last quarter. Mackenzie Financial Corp raised its position in BioNTech by 86.5% in the 3rd quarter. Mackenzie Financial Corp now owns 5,131 shares of the company’s stock worth $558,000 after purchasing an additional 2,380 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in BioNTech by 9.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 81,103 shares of the company’s stock valued at $8,811,000 after purchasing an additional 6,682 shares during the last quarter. Finally, Flossbach Von Storch AG raised its stake in shares of BioNTech by 2.1% during the third quarter. Flossbach Von Storch AG now owns 3,513,215 shares of the company’s stock valued at $381,676,000 after acquiring an additional 71,468 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.